Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Idec’s Tecfidera Goes To Market With Claim For Delay Of Disability Progression

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved the oral multiple sclerosis drug March 27 to treat patients with relapsing forms of the disease. Labeling includes data from one trial that showed patients on Tecfidera experienced disability progression less often.

You may also be interested in...



With Tecfidera, Biogen Idec Delivers Best MS Product Launch Yet

Biogen Idec blew past Wall Street estimates in its first quarter of revenue for its new, oral multiple sclerosis drug. But the biotech attributed much of the unexpected upside to quick conversions from another of its MS products, Tysabri.

Alkermes Moves Beyond Reformulations As It Preps Three New Compounds For Clinic

Alkermes multi-year efforts to move up from its successful reformulations for partners takes a step forward as the biotech presents its expanding clinical pipeline to investors, highlighting early-stage compounds for multiple sclerosis, pain and cancer.

Alkermes Moves Beyond Reformulations As It Preps Three New Compounds For Clinic

Alkermes multi-year efforts to move up from its successful reformulations for partners takes a step forward as the biotech presents its expanding clinical pipeline to investors, highlighting early-stage compounds for multiple sclerosis, pain, and cancer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel